Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs NKTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NKTX Captures Overall Composite Edge (50.5 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars

NKTX Overall Winner 6-Pillar Tally: FDMT 3 – 2 NKTX (1 Tie) Matrix Metrics: FDMT 5 – 3 NKTX

As of Nov 16, 2026, Nkarta, Inc. (NKTX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.5/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus NKTX at $1.21 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NKTX 50.5/100 HOLD), NKTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile NKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs NKTX
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07
NKTX NASDAQ Head-to-Head Winner
Nkarta, Inc. Common Stock
Pharmaceutical Preparations
$1.21
+1.26% 1D
Market Cap $90.6M
TTM Revenue $385
Forward P/E N/M
Beta / 30D Vol 1.89β · 117% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 43.0 Fund 59.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.6%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $1.58 · SMA50: $2.17

6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 NKTX)

Columns: Metric · FDMT · NKTX
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $385
Market Cap $669.3M $90.6M
3. Profitability & Quality NKTX
Gross Margin N/A N/A
Operating Margin -222.7% 0.0%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -46.6%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$156M -$94M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $49M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NKTX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 82.4% (10th %ile) 0.0% (<1st %ile)
Put/Call OI Skew 5.16x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (5) vs NKTX (3)
Institutional Metric FDMT NKTX Criterion Row Edge
Market Capitalization
Scale
$669.3M $90.6M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% +0.0% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% 0.0% Higher Margin NKTX
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin NKTX
Return on Equity (ROE)
Capital Efficiency
-56.7% -46.6% Higher ROE NKTX
52-Week Range Position
Momentum
47% ($7–$17) 4% ($1–$4) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 1.89β · 117% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
51.3 / 100 (HOLD) 50.5 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$96M $385 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$94M ($49M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +29.02 pp
FDMT: -4.04% · NKTX: -33.06%
3M Horizon FDMT +29.14 pp
FDMT: -20.86% · NKTX: -50.0%
6M Horizon FDMT +94.31 pp
FDMT: +39.27% · NKTX: -55.04%
1Y Horizon FDMT +49.23 pp
FDMT: +13.33% · NKTX: -35.9%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue NKTX Revenue FDMT Op. Margin NKTX Op. Margin Margin Leader
FY2019 $10M $0M -729.4% -19433.9% FDMT
FY2020 $10M N/A -424.0% N/A FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M N/A -3516.5% N/A FDMT
FY2023 $20M N/A -544.6% N/A FDMT
FY2024 $0M N/A -507678.4% N/A FDMT
FY2025 $90M N/A -187.2% N/A FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NKTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact NKTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NKTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs NKTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Nkarta, Inc. (NKTX) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (50.5/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus NKTX at $1.21 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. NKTX 50.5/100 HOLD), NKTX captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -222.7% operating margin) and revenue trajectory (+0.0% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile NKTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with NKTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $385 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while NKTX shifted N/A. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NKTX.

FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas NKTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus NKTX (-46.6% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, NKTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.89β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.